Dapagliflozin is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) in development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin is a synthetic C-glucoside compound classified as a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. Supplied as a stable, crystalline powder, it demonstrates high solubility in organic solvents and notable resistance to enzymatic hydrolysis. By inhibiting SGLT2 in renal proximal tubules, dapagliflozin modulates glucose reabsorption and fosters glycosuric effects, making it a valuable tool in metabolic and renal research. Frequently utilized in studies of glucose homeostasis, cellular transport mechanisms, and metabolic pathway modulation, dapagliflozin supports advanced biochemical investigations.
Products > Drug Discovery > Impurities > Anti-Diabetic > Dapagliflozin and Impurities | Products > Drug Discovery > Inhibitor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye